Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage biotechnology company developing small-molecule therapies for retinal disease. The KPRX news feed highlights company announcements on its development pipeline, clinical trial progress, strategic partnerships, and intellectual property related to its lead programs KIO-301 and KIO-104.
Recent news releases describe ongoing Phase 2 clinical trials for retinal diseases. The ABACUS-2 trial evaluates KIO-301, a molecular photoswitch being developed for vision restoration in patients with retinitis pigmentosa, with plans to expand into choroideremia and Stargardt disease. The KLARITY study investigates KIO-104, a non-steroidal, immuno-modulatory DHODH inhibitor, in patients with retinal inflammation and macular edema across several inflammatory retinal diseases, including posterior non-infectious uveitis and diabetic macular edema.
Investors following KPRX news can review quarterly financial updates, as Kiora reports research and development spending, collaboration credits, and cash position alongside clinical development updates. Press releases also cover collaboration agreements, such as the exclusive co-development and commercialization relationship with Théa Open Innovation for KIO-301 outside Asia and the option agreement with Senju Pharmaceutical for key Asian markets.
The news stream further includes information on new U.S. patents that expand protection for KIO-104 and the KIO-100 family of compounds, as well as Kiora’s participation in initiatives like the RARE-X Vision Consortium for rare ocular disorders. For those tracking the KPRX stock and the company’s retinal disease programs, this page aggregates Kiora’s official news, conference participation announcements, and other disclosures in one place.
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced the appointment of Dr. Roger A. Goldberg, a renowned vitreoretinal surgeon, to its Scientific Advisory Board on June 25, 2024. Dr. Goldberg, who is affiliated with Bay Area Retina Associates, brings extensive clinical and research expertise to Kiora. He has been involved in numerous clinical trials and has published extensively in top medical journals.
Dr. Goldberg will contribute to the development of Kiora's retinal disease therapeutics, including their investigational drug KIO-104, which targets overactive immune cells associated with conditions like macular edema and uveitis. His appointment is expected to enhance Kiora’s ability to advance treatment options for retinal diseases with high unmet needs. Dr. Goldberg’s background includes a medical degree from Yale, residency at Bascom Palmer Eye Institute, and a fellowship at Tufts University. He is board certified and actively engaged in several prestigious ophthalmology organizations.
Kiora Pharmaceuticals (NASDAQ: KPRX) will participate in two upcoming investor conferences. On May 22, at 3:00 pm ET, Executive VP of Finance Melissa Tosca will present at the WeBull Corporate Connect Biotech Investment Webinar. The event will be live and available on-demand for 90 days. On May 30, at 2:45 pm ET, President and CEO Brian Strem will join a virtual fireside chat at the Lytham Partners Spring 2024 Investor Conference. This event will also be live-streamed and available on-demand for 90 days. Kiora's management will hold one-on-one virtual meetings during the Lytham Partners event. Interested parties can arrange meetings by contacting Lytham Partners or registering for the event.
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) reported strong Q1 2024 financial results and updates on its retinal disease treatment pipeline. With $31.3 million in cash, Kiora is well-positioned to advance KIO-301 and KIO-104 into mid-stage clinical trials. The partnership with Théa Open Innovation (TOI) allows for efficient capital allocation. KIO-301 targets inherited retinal disorders, while KIO-104 addresses retinal inflammatory diseases. Positive milestones include successful Phase 1 trials and a strategic partnership with TOI. Financially, Kiora ended Q1 2024 with $31.3 million in cash, $16 million in revenue, and a net income of $13.5 million.
Kiora Pharmaceuticals (NASDAQ: KPRX) will be presenting at The Citizens JMP Life Sciences Conference on May 14th, 2024. Investors can access the online presentation live on the company's website and replay it for 90 days.
Kiora Pharmaceuticals released additional clinical data for KIO-301, a small molecule photoswitch, showing a significant increase in brain activity in the visual cortex of patients with retinitis pigmentosa. The data from the ABACUS-1 trial indicated improvements in visual field, visual acuity, and functional vision, along with an increase in neural activity that aligns with these improvements. The results were presented at the ARVO annual meeting by Professor Robert James Casson, supporting the drug's potential to restore vision.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.